Company news
Starpharma Holdings Limited news in 2017
Starpharma Holdings Limited's news releases, calls and decks from 2017, newest first.
VivaGel BV treatment clinical submission under rolling NDA
December 20, 2017
NDA submission for VivaGel BV in the US
November 21, 2017
VivaGel BV granted marketing approval in Australia
October 24, 2017
Starpharma and Peter Mac Cancer Centre awarded DEP Grant
October 9, 2017
AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor
September 28, 2017
DEP docetaxel positive phase 1 results, phase 2 commences
September 22, 2017
Starpharma and Monash awarded STEM Business Fellowships
August 9, 2017
Successful VivaGel Phase 3 results and NDA planned for rBV
August 6, 2017
VivaGel BV phase 3 results timing and commercialisation
July 4, 2017
Starpharma sells Agrochemicals business to Agrium for $35M
June 13, 2017
DEP irinotecan outperforms irinotecan in cancer models
June 5, 2017
AstraZeneca DEP candidate advance triggers milestone to SPL
April 19, 2017
Ansell launches VivaGel condom in Canada
April 11, 2017
VivaGel BV phase 3 trials for prevention of BV completed
March 29, 2017
Shareholder Update January 2017
January 18, 2017
VivaGel BV granted QIDP and Fast Track designation by US FDA
January 11, 2017
Decks in 2017
- Shareholder Meeting (November 2017)
Shareholder meeting · 45 slides · Nov 29, 2017
- Merger or Acquisition (June 2017)
Merger or acquisition · 12 slides · Jun 14, 2017